Press Releases
ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026
NEWTOWN SQUARE, Pa., Oct. 25, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced initial encouraging Phase 1 results for ARR-217, (MRG007), a cadherin-17 (CDH17)-targeting antibody-drug conjugate (ADC) developed in partnership with Lepu Biopharma Co., Ltd., in patients with gastrointestinal malignancies. The findings were presented as part of an oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress 2026...
Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM)
Pre-specified and Statistically Powered Key Endpoints Included Progression-free Survival (PFS) and Overall Survival (OS). Although Primary Endpoint of PFS Was Not Met, The Key Secondary Endpoint of OS Was Improved With VAZKEPA/VASCEPA
Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
Media Release COPENHAGEN, Denmark; October 25, 2026 Petosemtamab demonstrates encouraging objective response rates (ORRs), with promising depth and durability of response, in first- and second-line metastatic colorectal cancer (mCRC) Data reinforces the ongoing global Phase 3 trials of petosemtamab in mCRC, which are actively enrolling patients Genmab A/S (Nasdaq: GMAB) today announced updated follow-up analyses from a Phase 2 trial evaluating petosemtamab, an investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), in combination with FOLFOX or FOLFIRI in patients with metastatic colorectal cancer (mCRC). At a median follow-up of 5.9 months in the first-line (1L) setting and 7.1 months in the second-line (2L) setting, confirmed and unconfirmed objective response rates (ORRs) were 75% and 67%, respectively, with an ORR of 81% observed among 1L patients with left-sided tumors...
NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development
Nearly 18 months of median follow-up, selection of the 8 mg/kg dose and FDA engagement strengthen the foundation for registrational development in first-line metastatic gastroesophageal adenocarcinoma Nearly 18 months of median follow-up, selection of the 8 mg/kg dose and FDA engagement strengthen the foundation for registrational development in first-line metastatic gastroesophageal adenocarcinoma
Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced early Phase 2 results from the mismatch repair-deficient (dMMR) colon cancer cohort of NEOASIS, an investigator-initiated pan-tumor study sponsored by the Netherlands Cancer Institute (NKI). NEOASIS is evaluating botensilimab (BOT), Agenus' multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus' anti-PD-1 antibody, given before surgery...
Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)
Longer-term data reflecting nearly 4 years of follow-up show a further reduction in the risk of death from 14% to 37% for those initially treated with Libtayo, despite an 88% crossover from the placebo arm upon recurrence
Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced updated results from the Phase 1 study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in patients with advanced clear cell renal cell carcinoma (ccRCC). The results were presented by Sumanta Pal, M.D., FASCO, professor and vice chair of academic affairs at City of Hope Comp...
BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
MAINZ, Germany, and PRINCETON, USA, October 25, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb Company (NYSE: BMY, “BMS”) today announced first data from the global Phase 2 ROSETTA Lung-107 clinical trial (NCT06841055) evaluating pumitamig, an investigational PD-L1xVEGF-A bispecific immunomodulator (BNT327/BMS986545), in combination with docetaxel in patients with metastatic non-small cell lung cancer (“NSCLC”) whose disease progressed on or after first-line immunotherapy plus chemotherapy...
Prospera Energy Announces Service Rig Update as Luseland Workovers Come Online at 3.3x Prior Rates
Calgary, Alberta--(Newsfile Corp. - October 24, 2026) - Prospera Energy Inc. (TSXV: PEI) (OTC Pink: GXRFF) ("Prospera", "PEI", the "Corporation", or the "Company") announces an update on its fall service rig program. All five Luseland wells worked over between September 21st and October 10th, 2026, have returned to production and have averaged a combined 53.5 bbl/d of oil since first oil, up from 16.0 bbl/d before the workovers...
Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026
Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, consistent with Phase 1b data; additional data from the PrisMN Phase 2 study anticipated in 2027
Teck Provides Update on Highland Valley Copper Operations
VANCOUVER, British Columbia, Oct. 24, 2026 (GLOBE NEWSWIRE) -- Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) (“Teck”) announced today that strike action by United Steelworkers (USW) Local 7619 has commenced at Teck's Highland Valley Copper (HVC) Operations in B.C.
CCC Investors Have Opportunity to Join CCC Intelligent Solutions Holdings Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $CCC--CCC Investors Have Opportunity to Join CCC Intelligent Solutions Holdings Inc. Fraud Investigation with SBS Law.
Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed results across serotypes from a Phase 2 study (NCT06524414) for its investigational 25-valent pneumococcal conjugate vaccine candidate, PF-07872412 (25vPnC), in infants. In the study, a four-dose series of 25vPnC elicited robust immune responses against all 25 serotypes and showed safety and tolerability comparable to four doses of PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine). These findings were shared today...
IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
Nearly 80% of Patients Were Alive at One Year Versus 53% with IMFINZI Alone and Progression-Free Survival More Than Tripled Late-Breaking Phase 3 DeLLphi-305 Results Presented in ESMO Presidential Symposium and Simultaneously Published in The New England Journal of Medicine Longer DeLLphi-303 Follow-Up Data Showed Median Overall Survival Exceeded 37 Months in First-Line Maintenance with IMDELLTRA and Either IMFINZI or TECENTRIQ THOUSAND OAKS, Calif., Oct. 24, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced landmark interim Phase 3 results showing that IMDELLTRA (tarlatamab-dlle) in combination with AstraZeneca's IMFINZI (durvalumab) reduced the risk of death by 58% as a first-line maintenance treatment for extensive stage small cell lung cancer (ES-SCLC) (hazard ratio [HR]: 0.42; 95% confidence interval [CI]: 0.32, 0.54; P
Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the VOLGA Phase III trial showed perioperative treatment with AstraZeneca's IMFINZI (durvalumab) in combination with neoadjuvant enfortumab vedotin (EV) demonstrated statistically significant and clinically meaningful improvements in the primary endpoint of event-free survival (EFS) and key secondary endpoint of overall survival (OS) in patients with muscle-invasive bladder cancer (MIBC) versus standard of care. Patients were ineligible...
Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk localised or locally advanced prostate cancer
BEERSE, BELGIUM , Oct. 24, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use of apalutamide plus hormone therapy (androgen deprivation therapy), given for six months before and after surgery, with radical prostatectomy alone in patients with high-risk localised or locally advanced prostate cancer.1 The apalutamide plus hormone therapy regimen reduced the risk of disease recurrence or death by 62% compared with surgery alone.1 The regimen also showed a nominal improvement in metastasis-free survival (MFS), with a 51% lower risk of metastasis or death.1 Patients receiving perioperative treatment also experienced longer time to subsequent therapy compared with surgery alone.1
Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer
New substudy results showed a 51% lower estimated risk of metastasis or death over time with perioperative apalutamide plus ADT compared with immediate surgery Twice as many patients remained free from subsequent treatment at three years with perioperative apalutamide plus ADT compared with surgery alone Results evaluated outcomes versus surgery alone, building on the primary results presented at ASCO 2026 NEW BRUNSWICK, N.J., Oct. 24, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use of apalutamide plus androgen deprivation therapy (ADT), given for six months before and after surgery, with radical prostatectomy alone in patients with high-risk localized or locally advanced prostate cancer...
Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors
CAMBRIDGE, Mass., Oct. 24, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced updated safety and efficacy data for zolucatetide, the first and only direct inhibitor of the β-catenin:TCF interaction, in patients with desmoid tumors. The data were presented today in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27, 2026, in Madrid, Spain. The updated results, based on a June 22, 2026, data cutoff, include data from both the dose escalation and dose optimization portions of the ongoing Phase 1/2 trial and reinforce the strong efficacy and favorable safety and tolerability profile observed with zolucatetide. Among response-evaluable patients who began treatment at a starting dose of ≥450 mg, zolucatetide demonstrated an objective response rate (ORR) of 72.2% (13/18) in a 32-week landmark analysis. A disease control rate (DCR) of 100% was observed across all 46 response-evaluable patients who received a starting dose of ≥450 mg, with no disease progression. Data from a three-arm randomized dose optimization trial supported selection of a 450 mg weekly induction regimen administered for four cycles, followed by 300 mg every two weeks for long-term maintenance. Following productive end-of-Phase 2 discussions, Parabilis has reached alignment with the U.S. Food and Drug Administration (FDA) on the selected dose and regimen, on the use of a placebo-controlled study design, and on progression-free survival (PFS) as the primary endpoint for registrational development. Parabilis plans to initiate the randomized, double-blind PEDESTAL Phase 3 trial (Phase 3 Evaluation of DESmoid Tumor Activity with zoLucatetide) in the first half of 2027, with topline results anticipated in 2029. “Desmoid tumors are chronic and life-altering for patients, often affecting people at a young age, and patients need treatments that can deliver rapid, deep and durable tumor responses with a tolerability profile suited for long-term treatment,” said Mathai Mammen, M.D., Ph.D., Chairman, CEO and President of Parabilis Medicines. “We designed zolucatetide to directly inhibit β-catenin:TCF, a historically undruggable target at the heart of the biology driving these tumors. The depth and consistency of responses we are seeing, together with the favorable safety and tolerability profile observed to date, reinforce our conviction that zolucatetide has the potential to deliver a truly differentiated medicine and meaningfully expand the number of patients who can benefit from treatment. We are very pleased with the clarity of the FDA's feedback on our registrational development strategy, and with our Phase 3 regimen selected, we are moving with urgency to bring this medicine to patients.” Updated Phase 1/2 Results As of the June 22, 2026, data cutoff, 76 patients with desmoid tumors had been enrolled and treated across all dose levels in the dose escalation and dose optimization portions of the trial. Median age was 37 years (range 19–80), and 69.7% of patients were female. The population included both patients who had previously been treated with and failed gamma-secretase inhibitors (GSIs) and patients naive to GSIs...
Semtech Brings 5G Network Slicing, FIPS 140-3 to IACP 2026
CAMARILLO, Calif.--(BUSINESS WIRE)--Semtech Corporation (Nasdaq: SMTC), a leading provider of high-performance semiconductors powering AI data center networking and intelligent, connected Internet of Things (“IoT”) devices worldwide, is adding new resilient communications building blocks to its AirLink 5G Networking Solutions. Semtech will demonstrate the new capabilities in booth #2964 at the International Association of Chiefs of Police (IACP) conference in Orlando, Fla. First responders rel...
ESMO 2026: NUBEQA® (darolutamide) Plus ADT and Radiation Therapy Reduces Risk of Metastasis or Death by 58% in Prostate Cancer Patients at High Risk of Recurrence
WHIPPANY, N.J.--(BUSINESS WIRE)--ESMO 2026: NUBEQA plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence.
BioInvent's BI-1808 and KEYTRUDA(R) Induce Durable Responses in Heavily Pretreated Platinum-Resistant Ovarian Cancer
BioInvent International (STO:BINV) - Updated efficacy data in 34 evaluable patients with a chemotherapy-free regimen; randomized Part C will add BI-1808 to the new standard of care.
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
COPENHAGEN, Denmark & WILMINGTON, Del.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Incyte (Nasdaq: INCY) today announced a clinical trial collaboration to evaluate petosemtamab, Genmab's investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), in combination with INCB161734, Incyte's investigational, potent and selective KRAS G12D inhibitor, and standard-of-care chemotherapy as a fi...
NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma
In 24 heavily pre-treated patients with advanced primary cutaneous melanoma whose cancer had progressed after multiple prior lines of therapy including anti-PD-1 therapy, data continue to show an acceptable safety profile and early signals of efficacy 41.7% (10/24) overall response rate (ORR) per RECIST 1.1, including 4 complete responses 75% (18/24) disease control rate (DCR) 17.8 months median Overall Survival Exploratory analysis in a subset of patients (n=8) identified IL-1β, a cytokine linked to treatment-induced anti-tumor immunity, as the most increased plasma cytokine after treatment Investigators concluded that these preliminary findings warrant further evaluation in randomized clinical trials for patients with primary cutaneous melanoma naïve or refractory to anti-PD-1 Data presented at the 2026 Congress of the European Society for Medical Oncology PARIS and CAMBRIDGE, Mass., Oct. 24, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced updated results from patients with anti-PD-1-resistant advanced primary cutaneous melanoma treated in the ongoing Phase 1 Study 1100...
Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
WILMINGTON, Del. & COPENHAGEN, Denmark--(BUSINESS WIRE)---- $INCY--Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer.
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
Media Release COPENHAGEN, Denmark and WILMINGTON, Del.; October 24, 2026 Phase 1/2 study will evaluate petosemtamab plus INCB161734 and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC) Genmab A/S (Nasdaq: GMAB) and Incyte (Nasdaq: INCY) today a nnounced a clinical trial collaboration to evaluate petosemtamab, Genmab's investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), in combination with INCB161734, Incyte's investigational, potent and selective KRAS G12D inhibitor, and standard-of-care chemotherapy as a first-line treatment for patients with metastatic colorectal cancer harboring a KRAS G12D mutation, an area with substantial unmet medical need...
Investor Notification: Penske Automotive Group ($PAG) Investors Are Reminded to Contact BFA Law About the Ongoing Investigation into $212.00 per Share Take-Private Merger Deal
BFA Law is investigating the announced $212.00 per share merger in which Roger Penske and Mistui & Co., Ltd. are set to acquire Penske Automotive Group, Inc.; current shareholders are notified to contact the firm.
Investor Notification: Six Flags ($FUN) Investors Are Reminded to Contact BFA Law About the Ongoing Securities Fraud Investigation to Recover Losses
BFA Law is investigating whether Six Flags Entertainment Corporation committed securities fraud relating to statements about its focus on safety, maintenance, and ride reliability. New York, New York--(Newsfile Corp. - October 24, 2026) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Six Flags Entertainment Corporation (NYSE: FUN) for potential securities fraud after its significant stock drop...
Investor Notification: Personalis, Inc. ($PSNL) Investors Are Reminded to Contact BFA Law About the Ongoing Investigation into $16.25 per Share Merger Deal
BFA Law is investigating the announced $16.25 per share merger in which Tempus AI, Inc., a commercial associate of Personalis, is set to acquire all outstanding Personalis stock; current stockholders are notified to contact the firm. New York, New York--(Newsfile Corp. - October 24, 2026) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that it is investigating the going private merger whereby Personalis, Inc. (NASDAQ: PSNL) is being taken private by Tempus AI, Inc. Personalis is incorporated in Delaware...
Investor Notification: CCC Intelligent Solutions Inc. ($CCC) Investors Are Reminded to Contact BFA Law About the Ongoing Securities Fraud Investigation to Recover Losses
BFA Law is investigating the announced $7.75 per share merger in which a coalition led by GTRC LLC and including Elliott Investment Management L.P. is set to acquire CCC Intelligent Solutions, Inc.; current shareholders are notified to contact the firm.
Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026
BOSTON, Oct. 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the publication of results from the positive Phase 2/3 COMPANION-002 study of tovecimig in combination with paclitaxel in patients with previously treated, advanced biliary tract cancer (BTC) in the Journal of Clinical Oncology (JCO). The results are also being presented today by Nilofer S. Azad, M.D., Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain. The full publication is available via open access at https://ascopubs.org/toc/jco/0/ja...
Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026
Median PFS was 21.5 months with the gedatolisib triplet and 11.5 months with the gedatolisib doublet versus 9.1 months with alpelisib + fulvestrant in patients who had no liver metastases
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne's solid tumor franchise. Mark Lanasa, M.D., Ph...
Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026
Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with similar activity observed across FR α expression levels Clinical activity with Sofe-M was maintained even in patients with prior PARP inhibitor exposure, patients who typically experience poor outcomes with platinum-based chemotherapy Sofe-M is currently being studied in both platinum-sensitive and platinum-resistant ovarian cancer in multiple Phase 3 studies as part of the FRAmework-01 master protocol INDIANAPOLIS, Oct. 24, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its investigational folate receptor alpha (FRα) antibody-drug conjugate (ADC) sofetabart mipitecan (Sofe-M) plus bevacizumab achieved a confirmed objective response rate (cORR) of 79% and a disease control rate (DCR) of 100% in patients with platinum-sensitive ovarian cancer (PSOC). A cORR of 79% or higher was seen in both poly (ADP-ribose) polymerase inhibitor (PARPi)-treated and PARPi-naïve patients...
Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting
Houston, Texas and Tuebingen, Germany, October 24, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced updated clinical trial data from its ongoing Phase 1b study with IMA402 PRAME bispecific and its Phase 1 study with IMA203CD8 PRAME cell therapy...
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
VANCOUVER, British Columbia, Oct. 24, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today presented new clinical data from the randomized dose-optimization portion of its ongoing Phase 1 study evaluating ZW191, a FRα-targeting antibody-drug conjugate (ADC), at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain...
Robot Consulting Announces Receipt of Nasdaq Delisting Determination and Request to Appeal such Determination Before a Hearings Panel
TOKYO, JP / ACCESS Newswire / October 24, 2026 / Robot Consulting Co., Ltd. (Nasdaq:LAWR) ("Robot Consulting" or the "Company"), a Japanese platform service provider focusing on human resource solutions and legal technology, announced it has received a delisting determination from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company of the Staff's determination to delist the Company's American Depository Shares ("ADSs") pursuant to Nasdaq Listing Rules 5101 and IM-5101-4...
Junshi Biosciences Announces Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS203 in Combination with Chemotherapy for the Treatment of Diffuse Large B-cell Lymphoma
SHANGHAI, China, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the first patient dosing has been completed in a randomized, open-label, multicenter phase 3 clinical study of the company's product, a recombinant humanized anti-CD20/CD3 bispecific antibody (code: JS203), in combination with chemotherapy compared to rituximab in combination with chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) (the JS203-003-III-DLBCL Study; NCT07808827). This study is the first registrational clinical study for JS203...
Slate Grocery REIT Announces Receipt of Interim Order, and Provides Meeting and Circular Details
TORONTO--(BUSINESS WIRE)--Slate Grocery REIT (TSX: SGR.U) (TSX: SGR.UN) (the “REIT”), an owner and operator of U.S. grocery-anchored real estate, announced today that it has obtained an interim order (the “Interim Order”) of the Ontario Superior Court of Justice (Commercial List) (the “Court”) in connection with the proposed acquisition by EP/BRX Holdings LLC (the “Purchaser”), a joint venture between an affiliate of Brixmor Property Group Inc. and affiliates of Everview Partners, L.P., of all...
Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
Research Will Use Lunit's AI-powered Pathology Platform to Analyze H&E Whole-Slide Images and Generate Scalable Insights into Tumor Microenvironment Biology SEOUL, South Korea, Oct. 24, 2026 /PRNewswire/ -- Lunit Inc. (KRX: 328130) and Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a research agreement to evaluate the use of Lunit SCOPE IO, Lunit's AI-powered pathology platform, for tumor microenvironment analysis in support of Summit's immuno-oncology development programs with ivonescimab. The effort will focus on applying Lunit SCOPE IO to hematoxylin and eosin-stained (H&E) whole-slide images to characterize tumor microenvironment features...
Genesis Healthcare Announces Effective Date of Chapter 11 Plan Following Consummation of Sale to West State Street
KENNETT SQUARE, Pa.--(BUSINESS WIRE)--Genesis Healthcare, Inc. (“Genesis”) today announced that its chapter 11 plan became effective, following the closing of the sale of substantially all of its operating assets to 101 W. State Street, LLC (“West State Street”) on October 14, 2026.On behalf of the Board of Directors, the Company thanks its management team, its employees and staff for their focus and dedication throughout the chapter 11 process. Despite a long and complex case, the Company's fin...
Therma Bright Announces up to $420,000 Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - October 23, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced medical device technologies, announces that it proposes to undertake a non-brokered private placement of up to 14,000,000 common shares (the "Shares") at a price of $0.03/Share for total proceeds of up to $420,000 (the "Offering"). In accordance with the policies of the TSX Venture Exchange ("TSXV"), the Company is relying on a minimum pricing exception to issue securities at less than $0.05 per listed security...
DENARIUS METALS FILES TORAL PROJECT TECHNICAL REPORT ON SEDAR+
TORONTO, Oct. 23, 2026 /PRNewswire/ -- Denarius Metals Corp. (Cboe CA: DMET) (OTCQX: DNRSF) ("Denarius Metals" or "the Company") announced today the filing of a National Instrument 43-101 – Standards of Disclosure for Mineral Projects compliant technical report in support of the Mineral Resource estimate for its 100%-owned Toral Project. The technical report, entitled "Technical Report on the Toral Zn-Pb-Ag Project, Leon Province, Castilla y Leon, Spain" with an effective date of July 24, 2026, was prepared by Resource Development Associates and supports the disclosures made by the Company in its news release dated September 9, 2026...
Kaplan Fox Urges Endava plc (DAVA) Investors to Contact the Firm Before the Deadline on November 30, 2026
New York, New York--(Newsfile Corp. - October 23, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Endava plc ("Endava" or the "Company") (NYSE: DAVA) on behalf of investors that purchased or otherwise acquired Endava securities between September 4, 2025 and September 21, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Endava and have suffered losses, you may CLICK HERE to contact us...
RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
ALISO VIEJO, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that on October 23, 2026, RxSight granted inducement stock options to purchase a total of 236,456 shares of RxSight's common stock to two new non-executive officer employees in connection with the commencement of their employment with RxSight. RxSight also agreed to grant inducement restricted stock units (RSUs) covering a total of 637,449 shares of RxSight's common stock to the same employees in connection with the commencement of their employment with RxSight, which RSUs are anticipated to be granted on or about November 3, 2026...
US Metro Bancorp Announces Third Quarter 2026 Results
GARDEN GROVE, Calif.--(BUSINESS WIRE)--US Metro Bancorp (OTCQX: USMT): US Metro Bancorp (“Bancorp”) is a bank holding company, with a single subsidiary, US Metro Bank (“Bank”). On a consolidated basis, Bancorp earned $3.1 million in the third quarter of 2026, compared to $3.5 million in the second quarter of 2026. For the nine months ending September 30, 2026, the consolidated Bancorp earned $9.9 million compared to $8.0 million for the nine months ending September 30, 2025. On a year-to-date b...
Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy
SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today presented new biomarker data from the Phase 3 PROTECT Study providing evidence that FILSPARI (sparsentan) may modify the underlying disease pathophysiology in people with IgA nephropathy (IgAN). Data were shared today in an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, CO.“These biomarker data provide new insight into how FILSPARI's dual mechanism of action may modify the unde...
Hawaiian Electric Industries to Announce Third Quarter 2026 Results November 6
HONOLULU--(BUSINESS WIRE)--HEI to Announce Third Quarter 2026 Results.
Club Offers for Travel Enthusiasts in Canada
TORONTO, Oct 23, 2026 /PRNewswire/ -- Travelzoo (NASDAQ: TZOO), the club for travel enthusiasts, announces three of many new Club Offers for Club Members in Canada. Rigorously vetted and negotiated for us travel enthusiasts: $799—COSTA RICA WEEK WITH FLIGHTS & CARWe think fall is an ideal time to visit Costa Rica; the scenery is lush and the crowds are gone...
Starcore Announces Results of Annual General Meeting
Vancouver, British Columbia--(Newsfile Corp. - October 23, 2026) - Starcore International Mines Ltd. (TSX: SAM) ("Starcore" or the "Company") reports the results of its annual general meeting of shareholders (the "Meeting") held on October 23, 2026, at which 19.28% of shareholders entitled to vote were present...
Mirasol Resources Announces Option Grants
VANCOUVER, British Columbia, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Mirasol Resources Ltd. (TSX-V: MRZ) (OTCPK: MRZLF) (the “Company” or “Mirasol”) announced today that the Board of Directors has approved the grant of 3,878,750 incentive stock options (“Options”) to employees, officers, directors and consultants of the Company...
Principal Real Estate Income Fund Announces Changes in Portfolio Management
DENVER--(BUSINESS WIRE)--Principal Real Estate Income Fund (the “Fund”), which is traded on the New York Stock Exchange under the symbol “PGZ,” announced Marc Peterson will retire from Principal Real Estate Investors, LLC (“PrinREI”), the dedicated real estate investment team of Principal Asset Management, on October 23, 2026, and will no longer serve as a portfolio manager of the Fund at that time. Kelly Rush, CIO of global real estate securities, will remain as co-portfolio manager of the Fu...
Graphano Energy Announces Amendment to Previously Announced Private Placement
Vancouver, British Columbia--(Newsfile Corp. - October 23, 2026) - Graphano Energy Ltd. (TSXV: GEL) (FSE: 97G0) ("Graphano" or the "Company") announces that, further to its news release dated October 5, 2026, it has amended the terms of its previously announced non-brokered private placement (the "Offering") to include a flow-through share component...
Caldwell Announces Sale of IQTalent
TORONTO, ON / ACCESS Newswire / October 23, 2026 / Caldwell (TSX:CWL)(OTCQX:CWLPF), a leading retained executive search firm, today announced it has completed the sale of substantially all of the net operating assets of its wholly owned subsidiary, IQTalent Partners, Inc., to WinMil, Inc. WinMil will continue to operate the business under the IQTalent name and brand. Caldwell acquired IQTalent in 2020 to broaden its service offerings into technology-enabled recruiting solutions at the professional level...
Black Rock Coffee Bar Continues Expansion in California with New Rancho Cucamonga Location
Scottsdale, AZ, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Black Rock Coffee Bar, the Oregon-born boutique coffee chain celebrated for its specialty coffees, teas, smoothies, and signature Fuel energy drinks, is growing its footprint in California with the opening of a new store in Rancho Cucamonga. The store, located at 11370 Fourth St, will officially open its doors on Sunday, October 25 th...
Kaplan Fox Alerts Baidu, Inc. (BIDU) Investors to an Approaching Lead Plaintiff Deadline on November 13, 2026
New York, New York--(Newsfile Corp. - October 23, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Baidu, Inc. ("Baidu" or the "Company") (NASDAQ: BIDU) on behalf of investors that purchased or otherwise acquired Baidu securities, including call options, between November 18, 2025 and August 17, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Baidu and have suffered losses, you may CLICK HERE to contact us...
Elme Communities Announces Suspended NYSE Trading; Anticipates Trading Will Begin OTC Effective October 26, 2026
BETHESDA, Md., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Elme Communities (“Elme” or the “Company”) today announced that the New York Stock Exchange (“NYSE”) has exercised its discretionary authority in accordance with Section 802.01D of the NYSE Listed Company Manual to commence proceedings to delist Elme's common shares of beneficial interest (the “Common Shares”) from the NYSE due to “abnormally low selling price” levels. The NYSE also immediately suspended trading of the Common Shares. Given the Company's previously adopted Plan of Sale and Liquidation (as defined below), Elme does not intend to appeal the NYSE's determination, and, therefore, it is expected that the Common Shares will be delisted...
Howard Hughes Holdings Set to Join S&P SmallCap 600
NEW YORK, Oct. 23, 2026 /PRNewswire/ -- Howard Hughes Holdings Inc. (NYSE: HHH) will replace Arcosa Inc. (NYSE: ACA) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, October 28. S&P 500 constituent CRH plc (NYSE: CRH) has acquired Arcosa in a deal that closed today, October 23...
Kaplan Fox Urges The Ensign Group, Inc. (ENSG) Investors to Contact the Firm Before the Deadline on December 7, 2026
New York, New York--(Newsfile Corp. - October 23, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against The Ensign Group, Inc. ("Ensign" or the "Company") (NASDAQ: ENSG) on behalf of investors that purchased or otherwise acquired Ensign securities between February 10, 2022 and June 18, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Ensign and have suffered losses, you may CLICK HERE to contact us...
Algo Grande Commissions Independent NI 43-101 Update to Capture First Year of Progress at Adelita
• First year on the record: Algo Grande has engaged Addison Mining Services ("Addison") to update the NI 43-101 technical report on the 100%-owned Adelita Project in Sonora, Mexico. • Independent Qualified Person on site: James Hogg (MSc, BSc, MAIG), CEO and Principal Geologist of Addison, visited the project from October 11 to 15, 2026 with João Rocha, EurGeol, VP Exploration, covering the principal targets, the core shack and field procedures...
NexgenRx Announces Declaration of Dividends
TORONTO, ON / ACCESS Newswire / October 23, 2026 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares.
Kaplan Fox Encourages Millrose Properties, Inc. (MRP) Investors to Contact the Firm Before the Deadline on December 8, 2026 for a Leadership Role
New York, New York--(Newsfile Corp. - October 23, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Millrose Properties, Inc. ("Millrose" or the "Company") (NYSE: MRP) on behalf of investors that purchased or otherwise acquired Millrose securities between February 7, 2025 and October 2, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Millrose and have suffered losses, you may CLICK HERE to contact us...
Zefiro Announces Closing of Non-Brokered Private Placement for Gross Proceeds of Approximately C$5.0 Million
Toronto, Ontario--(Newsfile Corp. - October 23, 2026) - ZEFIRO METHANE CORP. (CBOE CA: ZEFI) (FSE: Y6B) (OTCQB: ZEFIF) (the "Company", "Zefiro", or "ZEFI") is pleased to announce that it has closed a non-brokered private placement for gross proceeds of approximately C$5.0 million (the "Offering").
BlackRock® Canada Announces the Termination of iShares Convertible Bond Index ETF
TORONTO, Oct. 23, 2026 (GLOBE NEWSWIRE) -- BlackRock Asset Management Canada Limited (“BlackRock Canada”), an indirect, wholly-owned subsidiary of BlackRock, Inc. (“BlackRock”) (NYSE:BLK) announced today that it intends to terminate iShares Convertible Bond Index ETF (the “Terminating Fund”), based on an ongoing process to review its product lineup. The Terminating Fund will terminate on or about January 21, 2027 (the “Termination Date”)...
Kaplan Fox Notifies Investors of Duolingo, Inc. (DUOL) of the Lead Plaintiff Deadline on December 7, 2026
New York, New York--(Newsfile Corp. - October 23, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Duolingo, Inc. ("Duolingo" or the "Company") (NASDAQ: DUOL) on behalf of investors that purchased or otherwise acquired Duolingo Class A common stock between May 2, 2025 and February 26, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Duolingo and have suffered losses, you may CLICK HERE to contact us...
Navios Maritime Holdings Inc. Extends Tender Offer for Its Series G and Series H American Depository Shares until 11:59 p.m. on November 2, 2026
GRAND CAYMAN, Cayman Islands, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Navios Maritime Holdings Inc. (“Navios Holdings” or the “Company”), announced today that it is extending the expiration date of its tender offer (the “Offer”) to purchase any and all outstanding Series H and Series G American Depositary Shares (the “Series G ADSs” and the “Series H ADSs”, together the “ADSs”) for cash, until 11:59 p.m., New York City Time, on November 2, 2026...
Itafos Announces Release Date for Q3 2026 Results and Business Update Webcast
HOUSTON, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Itafos Inc. (TSX-V: IFOS) (OTCQX: ITFS) (“Itafos” or “the Company”) today announces that its financial results for Q3 2026 will be released after market close on Wednesday, November 4, 2026. An on-demand recorded webcast of management commentary that reviews the Q3 2026 financial results, provides an update on the business, and addresses analysts' and investors' recent frequently asked questions will be available on Thursday, November 5, 2026, at 9:30 a.m. ET. The webcast will be available on the Presentations & Events page of the Company's website www.itafos.com/investors/presentations-fact-sheets/ and will be available for 90 days...
Kaplan Fox Reminds Coastal Financial Corporation (CCB) Investors to Seek a Leadership Role Before Deadline on December 1, 2026
New York, New York--(Newsfile Corp. - October 23, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Coastal Financial Corporation ("Coastal Financial" or the "Company") (NASDAQ: CCB) on behalf of investors that purchased or otherwise acquired Coastal Financial common stock between October 28, 2024 and July 29, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Coastal Financial and have suffered losses, you may CLICK HERE to contact us...
Vital Farms Introduces a Higher Standard for Free-Range Eggs Through Limited Pilot at Select Target Retail Stores
AUSTIN, Texas--(BUSINESS WIRE)--Vital Farms (Nasdaq: VITL) announced today the pilot launch of Vital Farms Free-Range eggs, which are expected to arrive in select Target retail stores across the South and Southeast beginning this week. This limited test is designed to explore how Vital Farms can reach more households with a high-quality product at a more accessible suggested retail price point of less than $5 per carton, while maintaining its commitment to transparency and animal welfare. Intro...
Notice to Market: Nu Holdings Ltd.
GRAND CAYMAN, Cayman Islands--(BUSINESS WIRE)--Nu Holdings Ltd. (NYSE: NU) (“Nu” or the “Company”), one of the world's largest digital banking platforms, announced that Eric Young, its Chief Technology Officer, has decided to resign to pursue a new professional opportunity. Mr. Young is expected to remain with the Company until November 12, 2026 to support an orderly transition.David Vélez, Founder, Chairman and Chief Executive Officer, will directly oversee Global Platforms on an interim basis,...
AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced it granted inducement equity awards to two newly-hired employees.On October 19, 2026, the Compensation Committee granted inducement equity awards to two newly hired employees consisting in the aggregate of options to purchase 10,565 shares of the Company's common stock and 5,2...
Kaplan Fox Notifies Investors of Alphabet Inc. (GOOGL, GOOG) of the Lead Plaintiff Deadline on December 1, 2026
New York, New York--(Newsfile Corp. - October 23, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Alphabet Inc. ("Alphabet" or the "Company") (NASDAQ: GOOGL) (NASDAQ: GOOG) on behalf of investors that purchased or otherwise acquired Alphabet securities between May 19, 2026 and July 16, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Alphabet and have suffered losses, you may CLICK HERE to contact us...
Portland General Electric Declares Dividend
Portland, Oregon--(Newsfile Corp. - October 23, 2026) - On October 23, 2026, the board of directors of Portland General Electric Company (NYSE: POR) declared a quarterly common stock dividend of $0.55125 per share. The company's dividend is evaluated based on capital requirements and financial performance...
The Eastern Company Announces Timing of Third Quarter 2026 Earnings Release and Conference Call
SHELTON, CT / ACCESS Newswire / October 23, 2026 / The Eastern Company (NASDAQ:EML), an industrial manufacturer of unique engineered solutions serving commercial transportation, logistics, and other industrial markets, will release financial results for the third quarter 2026 after the market close on Tuesday, November 10, 2026. Management will hold a conference call and webcast on Wednesday, November 11, 2026 at 9:00 a.m...
Kaplan Fox Reminds Gildan Activewear Inc. (GIL) Investors with Significant Losses to Seek a Leadership Role Before Deadline on December 14, 2026
New York, New York--(Newsfile Corp. - October 23, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Gildan Activewear Inc. ("Gildan" or the "Company") (NYSE: GIL) on behalf of investors that purchased or otherwise acquired Gildan securities between February 19, 2025 and June 15, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Gildan and have suffered losses, you may CLICK HERE to contact us...
First Capital, Inc. Reports Quarterly Earnings
CORYDON, Ind., Oct. 23, 2026 (GLOBE NEWSWIRE) -- First Capital, Inc. (the “Company”) (NASDAQ: FCAP), the holding company for First Harrison Bank (the “Bank”), today reported net income of $5.1 million, or $1.53 per diluted share, for the quarter ended September 30, 2026, compared to net income of $4.5 million, or $1.34 per diluted share, for the quarter ended September 30, 2025...
Myers Industries Announces Quarterly Dividend
AKRON, Ohio--(BUSINESS WIRE)--Myers Industries Announces Quarterly Dividend.
Rocket Doctor Grants Equity
Vancouver, British Columbia, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Rocket Doctor AI Inc. ( CSE: AIDR , OTC: AIRDF , Frankfurt: 939) (“Rocket Doctor AI” or the “Company”) announces that it has granted an aggregate 3,143 stock options, exercisable at $0.70 per share and valid for a term of three years, and an aggregate 239,000 restricted share units, valid for a term between three to five years, to an officer of the Company and to consultants and employees of the Company's subsidiary. The stock options and restricted share units are issued pursuant to the Company's share compensation plans and all restricted share units and stock options are subject to vesting over up to one year. All securities are subject to a hold period of four months and one day in accordance with applicable securities laws and policies of the Canadian Securities Exchange...
Kaplan Fox Reminds Ardelyx, Inc. (ARDX) Investors to Seek a Leadership Role Before Deadline on November 16, 2026
New York, New York--(Newsfile Corp. - October 23, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX) on behalf of investors that purchased or otherwise acquired Ardelyx common stock between January 13, 2025 and August 6, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Ardelyx and have suffered losses, you may CLICK HERE to contact us...
Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
MIAMI & SEOUL, South Korea--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) and Lunit Inc. (KRX: 328130) today announced a research agreement to evaluate the use of Lunit SCOPE IO, Lunit's AI-powered pathology platform, for tumor microenvironment analysis in support of Summit's immuno-oncology development programs with ivonescimab. The effort will focus on applying Lunit SCOPE IO to hematoxylin and eosin-stained (H&E) whole-slide images to characterize tumor microenvironment featur...
Oxford Square Capital Corp. Schedules Third Quarter 2026 Earnings Release and Conference Call for October 30, 2026
GREENWICH, Conn., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Oxford Square Capital Corp. (NasdaqGS: OXSQ) (NasdaqGS: OXSQG) (NasdaqGS: OXSQH) announced today that it will hold a conference call to discuss third quarter 2026 earnings on Friday, October 30, 2026 at 9:00 AM Eastern time. The toll free dial-in number is 1-800-715-9871, access code number 5885175. There will be a recorded replay of the call available for 30 days after the call. If you are interested in hearing the recording, please dial 1-800-770-2030. The replay pass-code is 5885175#...
Carriage Services Announces 2026 Third Quarter Earnings Release and Conference Call Schedule
HOUSTON, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Carriage Services, Inc. (NYSE: CSV) today announced plans to release 2026 third quarter results on Wednesday, November 4, 2026, after the market closes. In conjunction with the release, Carriage Services has scheduled a conference call, which will be broadcast live via webcast on Thursday, November 5, 2026, at 8:00 a.m. Central Time...
Ares Commercial Real Estate Corporation Schedules Earnings Release and Conference Call for the Third Quarter Ended September 30, 2026
NEW YORK, Oct. 23, 2026 /PRNewswire/ -- Ares Commercial Real Estate Corporation (NYSE: ACRE) announced today that it will report earnings for the third quarter ended September 30, 2026 on Friday, November 6, 2026 prior to the opening of the New York Stock Exchange. Ares Commercial Real Estate Corporation will hold its webcast/conference call on the same day at 10:00 a.m...
Amy Johnson Appointed President of GDIT
RESTON, Va., Oct. 23, 2026 /PRNewswire/ -- General Dynamics (NYSE:GD) announced today that Amy Johnson has been appointed as president of GDIT, effective November 3.
Avanti Gold Announces Results of Annual General and Special Meeting
Vancouver, British Columbia--(Newsfile Corp. - October 23, 2026) - Avanti Gold Corp. (CSE: AGC) (FSE: X370) (OTCQB: AVTGF) ("Avanti" or the "Company") Announces the results of the Company's Annual General and Special Meeting of Shareholders ("AGSM") held October 23, 2026. ELECTION OF DIRECTORS At the AGSM, shareholders elected Matthieu Bos, George Bennett, Eric Zurrin, Terrence Holohan, and Martin Pawlitschek as directors of the Company, to hold office until the next annual meeting of shareholders or until their successors are elected or appointed...
ENERGY SERVICES OF AMERICA COMPLETES FAMCO ACQUISITION
HUNTINGTON, W.Va., Oct. 23, 2026 /PRNewswire/ -- Energy Services of America Corporation (the "Company" or "Energy Services") (Nasdaq: ESOA) today announced that its subsidiary, FAMCO Acquisition, Inc., has completed the acquisition of substantially all of the operating assets of FAMCO, Inc. ("FAMCO"), a West Virginia utility contractor focused primarily on water and sewer infrastructure...
Delek Logistics Partners, LP Increases Quarterly Cash Distribution to $1.14 per Common Limited Partner Unit
BRENTWOOD, Tenn.--(BUSINESS WIRE)--Delek Logistics Partners, LP (NYSE: DKL) (“Delek Logistics”) today declared its quarterly cash distribution for the third quarter 2026 of $1.14 per common limited partner unit, or $4.56 per common limited partner unit on an annualized basis. The third quarter 2026 cash distribution is payable on November 10, 2026, to unitholders of record on November 3, 2026. About Delek Logistics Partners, LP Delek Logistics is a midstream energy master limited partnership he...
California American Water Submits Monterey Desalination Project Financing and Cost Updates to the California Public Utilities Commission
The filing underscores the Monterey Peninsula's continued need for drought-proof water supplies and describes strategies to be implemented to offset project cost PACIFIC GROVE, Calif., Oct. 23, 2026 /PRNewswire/ -- Today, California American Water submitted an application to the California Public Utilities Commission (CPUC) updating the project cost estimates, a low-cost financing framework, and a proposal for rate treatment for the Monterey Peninsula Water Supply Project's desalination facilities...
PERMIAN BASIN ROYALTY TRUST ANNOUNCES RECORD DATE AND MEETING DATE FOR SPECIAL MEETING TO CONSIDER SOFTVEST PROPOSALS
DALLAS, Oct. 23, 2026 /PRNewswire/ -- Argent Trust Company, as trustee ("Trustee") of the Permian Basin Royalty Trust (NYSE: PBT) ("Permian" or the "Trust"), today announced that it has received a request from SoftVest Advisors, LLC ("SoftVest"), together with other holders of units of beneficial interest ("Units") who collectively with SoftVest own more than 15% of the outstanding Units of the Trust, to call a special meeting ("Special Meeting") of the Trust's Unit holders to be held on November 23, 2026, with a record date of October 13 , 2026. The purpose of the Special Meeting requested by the Unit holders is to present for a vote by the Trust's Unit holders (i) a proposal to approve and adopt the terms of an amendment to the Trust Indenture to effect the Business Combination pursuant to the Combination Agreement (as set forth in the proxy statement / prospectus included in the Form S-4 filed with the Securities and Exchange Commission by PBT Land and Minerals, Inc. ("New PBT"), SoftVest, SoftVest, L.P...
Kaplan Fox Encourages FuelCell Energy, Inc. (FCEL) Investors Seeking Recovery to Contact the Firm Before November 10, 2026
New York, New York--(Newsfile Corp. - October 23, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against FuelCell Energy, Inc. ("FuelCell" or the "Company") (NASDAQ: FCEL) on behalf of investors that purchased or otherwise acquired FuelCell securities between June 24, 2026 and September 1, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in FuelCell and have suffered losses, you may CLICK HERE to contact us...
Aberdeen Multi-Market Income Fund (MMT) Announces Upcoming 1-for-4 Reverse Stock Split
PHILADELPHIA, Oct. 23, 2026 /PRNewswire/ -- The Board of Trustees of Aberdeen Multi-Market Income Fund (NYSE: MMT) has approved a 1-for-4 reverse stock split of the Fund's issued and outstanding common shares, effective prior to the opening of trading on November 9, 2026. The Board approved the reverse stock split to increase the Fund's per-share market price...
J-Star Holding Co., Ltd. Files Interim Financial Report on Form 6-K
Company is Highlighting Strategic Focus on U.S. Opportunities, Balance Sheet Improvement, and Management Commitment Company is Highlighting Strategic Focus on U.S. Opportunities, Balance Sheet Improvement, and Management Commitment